FCM
ELEV

Farallon Capital Management’s Elevation Oncology ELEV Stock Holding History

Farallon Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,527,482
Closed -$1.98M – 150
2024
Q4 		$1.98M Hold
3,527,482
– – 0.01% 96
2024
Q3 		$2.12M Sell
3,527,482
-70,936
-2% -$105K 0.01% 104
2024
Q2 		$9.72M Sell
3,598,418
-288,245
-7% -$1.09M 0.04% 83
2024
Q1 		$19.9M Buy
+3,886,663
New +$12.6M 0.08% 75

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Farallon Capital Management's ELEV Position: Q1 2025 in Review

Farallon Capital Management sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 3,527,482 shares — an estimated $1.98M sold.

Farallon Capital Management first reported a position in ELEV in Q1 2024 and held it in 4 quarters. The position peaked at $19.9M in Q1 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • Farallon Capital Management reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • Farallon Capital Management sold 3,527,482 Elevation Oncology shares in Q1 2025, an estimated $1.98M.
  • Farallon Capital Management first reported a position in Elevation Oncology in Q1 2024 and held it in 4 quarters.
  • Farallon Capital Management's Elevation Oncology position peaked at $19.9M in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on Farallon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.